Island Pharmaceuticals (ASX:ILA) Shares Buyback Ratio %: -48.16 (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ILA Island Pharmaceuticals Ltd ASX:ILA
27 GF Score
Price A$0.45
! 1 Warning Sign
View Full Analysis

What is Island Pharmaceuticals Shares Buyback Ratio %?

Island Pharmaceuticals ASX:ILA 27 Shares Buyback Ratio % is -48.16 as of Aug. 08, 2026. GuruFocus rates ASX:ILA with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Island Pharmaceuticals's current shares buyback ratio was -48.16%.

Island Pharmaceuticals Shares Buyback Ratio % Related Terms

Island Pharmaceuticals Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Island Pharmaceuticals's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Island Pharmaceuticals Shares Buyback Ratio % Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Shares Buyback Ratio %
0.00 -0.37 0.00 -44.84 -86.24

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 -44.84 -43.25 -30.01 -13.96
ASX:ILA
27GF Score
Island Pharmaceuticals Ltd ASX:ILA
Shares Buyback Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Island Pharmaceuticals Shares Buyback Ratio % Calculation

Island Pharmaceuticals's Shares Buyback Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2024 ) - Shares Outstanding (EOP) (A: Jun. 2025 )) / Shares Outstanding (EOP) (A: Jun. 2024 )
=(126.767 - 236.093) / 126.767
=-86.24%

Island Pharmaceuticals's Shares Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2025 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Jun. 2025 )
=(236.093 - 269.052) / 236.093
=-13.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -48.16 mean?
Island Pharmaceuticals (ASX:ILA) has a Shares Buyback Ratio % of -48.16 as of Aug. 08, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Island Pharmaceuticals and its competitors.
Is Island Pharmaceuticals' Shares Buyback Ratio % too high?
Island Pharmaceuticals' current Shares Buyback Ratio % is -48.16. Overall, Island Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' Shares Buyback Ratio % compare to VRTX and REGN?
Island Pharmaceuticals' Shares Buyback Ratio % of -48.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Island Pharmaceuticals and its competitors. Island Pharmaceuticals's current Shares Buyback Ratio % is -48.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current Shares Buyback Ratio % of -48.16. The current Shares Buyback Ratio % is -48.16. Island Pharmaceuticals' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current Shares Buyback Ratio % is -48.16 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Island Pharmaceuticals Business Description

Address c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
27GF Score

Get the complete analysis for ASX:ILA

Shares Buyback Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.45
Price